Select a medication above to begin.
Paxlovid
nirmatrelvir and ritonavir
Black Box Warnings .
Significant Drug Interactions
ritonavir, a strong CYP3A inhibitor, may cause incr. exposure of certain medications, resulting in potential severe, life-threatening or fatal events; review all medications to assess potential drug interactions and determine if dose adjustment, interruption, or additional monitoring required; consider benefit of reduced hospitalization and death and risk of appropriate drug interaction management
Adult Dosing .
Dosage forms: 150 mg/100 mg convenience pack; 300 mg/100 mg convenience pack
Special Note
- [150 mg/100 mg convenience pack components]
- Info: pack contains 10 single-dose blister cards w/ nirmatrelvir 150 mg tab x1 and ritonavir 100 mg x1
- [300 mg/100 mg convenience pack components]
- Info: pack contains 10 single-dose blister cards w/ nirmatrelvir 150 mg tab x2 and ritonavir 100 mg x1
- [strength clarification]
- Info: 1 dose = 300 mg nirmatrelvir + 100 mg ritonavir
COVID-19, mild-moderate
- [1 dose PO bid x5 days]
- Start: ASAP w/in 5 days of sx onset; Info: for pts at high risk for severe dz incl. hospitalization or death; use 300 mg/100 mg convenience pack; do not cut/crush/chew tab
renal dosing
- [see below]
- eGFR 30-59: nirmatrelvir 150 mg + ritonavir 100 mg bid, use 150 mg/100 mg convenience pack; eGFR <30: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined
Peds Dosing .
- Dosage forms: 150 mg/100 mg convenience pack; 300 mg/100 mg convenience pack
Special Note, COVID-19
- [FDA emergency use authorization (EUA)]
- Info: for mild-moderate COVID-19 in pts at high risk for severe dz incl. hospitalization or death; avail. from Pfizer Inc. or authorized distributors as directed by US government; for clinical trial eligibility and enrollment info, check www.clinicaltrials.gov
- [mandatory reporting]
- Info: serious medication errors and adverse events must be reported to FDA MedWatch (www.fda.gov/medwatch/report.htm or 1-800-FDA-1088) and Pfizer Inc. (1-800-438-1985)
Special Note
- [150 mg/100 mg convenience pack components]
- Info: pack contains 10 single-dose blister cards w/ nirmatrelvir 150 mg tab x1 and ritonavir 100 mg x1
- [300 mg/100 mg convenience pack components]
- Info: pack contains 10 single-dose blister cards w/ nirmatrelvir 150 mg tab x2 and ritonavir 100 mg x1
- [strength clarification]
- Info: 1 dose = 300 mg nirmatrelvir + 100 mg ritonavir
COVID-19, mild-moderate
- [12 yo and older, >40 kg]
- Dose: 1 dose PO bid x5 days; Start: ASAP w/in 5 days of sx onset; Info: per FDA EUA; for pts at high risk for severe dz incl. hospitalization or death; use 300 mg/100 mg convenience pack; do not cut/crush/chew tab
renal dosing
- [see below]
- eGFR 30-59: nirmatrelvir 150 mg + ritonavir 100 mg bid, use 150 mg/100 mg convenience pack; eGFR <30: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined